Comparison of Clinical Manifestations and Related Factors of Hepatocellular Carcinoma with Chronic Hepatitis B.

Haisong Hou, Liu Liang, Lihong Deng, Wanping Ye, Yuanzhang Wen, Jun Liu
Author Information
  1. Haisong Hou: Laboratory of Pathogenic Biology, Guangdong Medical University, Zhanjiang, People's Republic of China.
  2. Liu Liang: Department of Laboratory Medicine, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.
  3. Lihong Deng: Department of Hepatology, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.
  4. Wanping Ye: Department of Gastroenterology, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.
  5. Yuanzhang Wen: Department of Hepatobiliary Surgery, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.
  6. Jun Liu: Laboratory of Pathogenic Biology, Guangdong Medical University, Zhanjiang, People's Republic of China.

Abstract

Background: The aim of this study was to describe the demographic and clinical characteristics of hepatitis B virus (HBV) associated hepatocellular carcinoma (HCC), analyse the risk factors associated with HBV-associated HCC, and to provide some references to the diagnosis and treatment of HCC.
Methods: This study retrospectively enrolled 730 patients, including 390 patients with chronic hepatitis B (CHB) as controls, and 340 patients with CHB complicated with HCC as patients. Relevant information and medical records of these participants were collected, including age, sex, cigarette smoking, alcoholism, diabetes mellitus (DM), hypertension, coronary heart disease (CHD), cirrhosis, occupation, ascites, HBV-DNA load, the qualitative analysis of HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb serological markers, and levels of alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), gamma-glutamyltransferase (GGT), TNM stage, tumor size and tumor number. The test, Chi-square test, non-parametric rank-sum test, logistic regression analyses were used to explore the influencing factors and their degree of association with HCC in patients with HBV.
Results: The proportion of smoking, alcoholism, married status, DM, hypertension, and the rate of HBV-DNA with a viral load of ≥500 copies/mL were significantly higher in the HCC group than in the controls (all <0.05). Cirrhosis was more common among patients with CHB+HCC than in controls (=0.013). The proportion of patients with HBsAg, HBeAb, and HBcAb positive was greater in CHB+HCC group than that in CHB group. Logistic regression analysis indicated that age ≥60 years (OR: 1.835, 95% CI: 1.020-3.302, =0.043), HBeAb positive (OR: 9.105, 95% CI: 4.796-17.288, <0.001), antiviral treatment with entecavir (OR: 2.209, 95% CI: 1.106-4.409, =0.025), and GGT (OR: 1.004, 95% CI: 1.001-1.007, =0.002) were risk factors for HCC in patients with CHB.
Conclusion: Advanced age, HBeAb positive, antiviral treatment with entecavir, and GGT were independent risk factors for HCC in HBV patients.

Keywords

References

  1. Zhonghua Gan Zang Bing Za Zhi. 2015 Dec;23(12):888-905 [PMID: 26739464]
  2. Gastroenterology. 2012 May;142(6):1264-1273.e1 [PMID: 22537432]
  3. World J Gastroenterol. 2018 Apr 7;24(13):1440-1450 [PMID: 29632425]
  4. Gut. 2022 Mar;71(3):616-626 [PMID: 33563643]
  5. Protein Cell. 2014 Sep;5(9):673-91 [PMID: 24916440]
  6. Open Virol J. 2018 Feb 28;12:26-32 [PMID: 29541276]
  7. World J Gastroenterol. 2021 Jul 14;27(26):4018-4044 [PMID: 34326611]
  8. J Hepatol. 2019 Sep;71(3):456-464 [PMID: 30959156]
  9. Hepatol Res. 2007 Jul;37(s1):S36-41 [PMID: 17627634]
  10. Lancet. 2015 Oct 17;386(10003):1546-55 [PMID: 26231459]
  11. Hepatology. 2014 Dec;60(6):1871-8 [PMID: 25065513]
  12. J Virol. 2001 Nov;75(21):10348-58 [PMID: 11581403]
  13. Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10 [PMID: 33965578]
  14. J Hepatol. 2020 Feb;72(2):250-261 [PMID: 31954490]
  15. Gastroenterology. 2020 Jan;158(1):215-225.e6 [PMID: 31574268]
  16. Gut. 2020 Jul;69(7):1301-1308 [PMID: 31672838]
  17. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1261-8 [PMID: 20447919]
  18. BMC Infect Dis. 2019 Sep 18;19(1):811 [PMID: 31533643]
  19. Int J Cancer. 2006 Oct 15;119(8):1946-52 [PMID: 16708389]
  20. Br J Cancer. 2010 Aug 24;103(5):741-6 [PMID: 20648009]
  21. Clin Gastroenterol Hepatol. 2019 Dec;17(13):2769-2775.e4 [PMID: 31009793]
  22. Hepatol Commun. 2020 Aug 09;4(10):1541-1551 [PMID: 33024922]
  23. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2071-87.e16 [PMID: 26188135]
  24. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  25. Hepatology. 2021 Jan;73 Suppl 1:4-13 [PMID: 32319693]
  26. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2793-2802.e6 [PMID: 32135246]
  27. J Hepatol. 2022 Dec;77(6):1598-1606 [PMID: 36208844]
  28. World J Gastroenterol. 2014 Oct 7;20(37):13546-55 [PMID: 25309085]
  29. Br J Cancer. 2018 Apr;118(7):1005-1012 [PMID: 29520041]
  30. Ecancermedicalscience. 2022 May 04;16:1383 [PMID: 35919232]
  31. Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):14-20 [PMID: 26499410]
  32. JAMA. 2006 Jan 4;295(1):65-73 [PMID: 16391218]
  33. Viruses. 2022 May 07;14(5): [PMID: 35632728]
  34. Liver Cancer. 2022 Aug 23;11(6):497-510 [PMID: 36589728]
  35. Life Sci. 2013 Jan 17;92(1):3-9 [PMID: 23123447]
  36. Clin Res Hepatol Gastroenterol. 2022 Feb;46(2):101781 [PMID: 34332136]
  37. Minerva Med. 2023 Oct;114(5):658-666 [PMID: 36912857]
  38. Cancer Med. 2020 May;9(9):3057-3069 [PMID: 32150664]
  39. Lancet Glob Health. 2022 Feb;10(2):e278-e287 [PMID: 35063115]
  40. Genes Dis. 2020 Dec 02;9(4):1024-1037 [PMID: 35685472]
  41. World J Gastroenterol. 2022 Apr 14;28(14):1405-1429 [PMID: 35582678]
  42. Pol J Microbiol. 2020 Dec;69(4):391-399 [PMID: 33574867]
  43. Radiology. 1989 Aug;172(2):389-92 [PMID: 2526349]
  44. J Hepatol. 2017 Feb;66(2):288-296 [PMID: 27650283]
  45. Int J Mol Sci. 2021 Jan 06;22(2): [PMID: 33418899]
  46. Chin Clin Oncol. 2013 Dec;2(4):38 [PMID: 25841917]
  47. J Hepatol. 2017 Nov;67(5):902-908 [PMID: 28652084]
  48. Afr Health Sci. 2022 Sep;22(3):561-566 [PMID: 36910386]
  49. BMC Gastroenterol. 2022 Feb 27;22(1):85 [PMID: 35220946]
  50. Diagn Pathol. 2014 Nov 25;9:199 [PMID: 25420786]
  51. World J Clin Cases. 2022 Sep 16;10(26):9545-9549 [PMID: 36159415]
  52. Liver Cancer. 2020 Dec;9(6):734-743 [PMID: 33442542]
  53. Emerg Microbes Infect. 2023 Dec;12(2):2259003 [PMID: 37702202]
  54. J Clin Oncol. 2008 Jan 10;26(2):177-82 [PMID: 18182659]
  55. J Clin Exp Hepatol. 2020 Jul-Aug;10(4):296-303 [PMID: 32655232]
  56. J Hepatol. 2024 Feb;80(2):232-242 [PMID: 38030035]
  57. Gastroenterology. 1996 Oct;111(4):1018-22 [PMID: 8831597]
  58. Clin Gastroenterol Hepatol. 2021 Feb;19(2):246-258.e9 [PMID: 32407970]
  59. J Hepatol. 2022 Jul;77(1):42-54 [PMID: 35149125]
  60. Expert Rev Gastroenterol Hepatol. 2023 Jan-Jun;17(6):623-633 [PMID: 37148261]
  61. J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6 [PMID: 23632345]
  62. JAMA Surg. 2023 Apr 1;158(4):410-420 [PMID: 36790767]

Word Cloud

Created with Highcharts 10.0.0patientsHCCB1hepatitisfactorsCHBHBeAb=0OR:95%CI:HBVrisktreatmentcontrolsageGGTtestgrouppositivestudyvirusassociatedhepatocellularcarcinomaincludingchronicsmokingalcoholismDMhypertensioncirrhosisHBV-DNAloadanalysisHBsAgHBcAbbilirubintumorregressionproportion<0CHB+HCCantiviralentecavirBackground:aimdescribedemographicclinicalcharacteristicsanalyseHBV-associatedprovidereferencesdiagnosisMethods:retrospectivelyenrolled730390340complicatedRelevantinformationmedicalrecordsparticipantscollectedsexcigarettediabetesmellituscoronaryheartdiseaseCHDoccupationascitesqualitativeHBsAbHBeAgserologicalmarkerslevelsalaninetransaminaseALTaspartateaminotransferaseASTtotalTBILdirectDBILgamma-glutamyltransferaseTNMstagesizenumberChi-squarenon-parametricrank-sumlogisticanalysesusedexploreinfluencingdegreeassociationResults:marriedstatusrateviral≥500copies/mLsignificantlyhigher05Cirrhosiscommonamong013greaterLogisticindicated≥60years835020-330204391054796-172880012209106-4409025004001-1007002Conclusion:AdvancedindependentComparisonClinicalManifestationsRelatedFactorsHepatocellularCarcinomaChronicHepatitis

Similar Articles

Cited By

No available data.